Moderna Falls, Celsius Climbs, Newsmax Skyrockets in Debut

On this episode of Stock Movers:

- Vaccine and biotech stocks, including Moderna (MRNA) plunged after a top regulator left the US Food and Drug Administration, casting deep uncertainty about the future of vaccines and cutting-edge gene therapies. Peter Marks, a key figure overseeing the review and approval of vaccines and other medications, resigned on Friday, citing friction with the views of new Health and Human Services Secretary and longtime vaccine critic Robert F. Kennedy Jr.

- Celsius Holdings (CELH) shares rose to hit its highest intraday level since September after Truist Securities upgraded its recommendation to buy from hold, saying the company’s Alani Nu acquisition gives it an “extremely strong position” in the women’s segment of the US energy drink category.

- Newsmax (NMAX) shares skyrocketed as much as 683% in their debut session, as individual investors piled into the conservative media outlet after its initial public offering. Shares were repeatedly halted for volatility. Newsmax raised $75 million in the offering, selling 7.5 million shares for $10 apiece. The mania for a loss-making cable news network stands in dramatic contrast with the year’s biggest and most high-profile IPOs, after Venture Global and CoreWeave realized valuations far less than initially proposed and have traded down in the days after their debuts.

See omnystudio.com/listener for privacy information.